Angiogenesis Inhibitors: all 4,430 studies that test it

Page 29 of 45. Open to participants first (542), then studies with results posted, then the rest; newest registration first within each.

• NM-IL-12 (rHuIL-12) in Subjects With Open Surgical WoundsCompletedNCT02544061Phase 2
• Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMDCompletedNCT02543229Phase 1
• Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple MyelomaActive, not recruitingNCT02542657Phase 1/2
• Lenalidomide Maintenance in Plasma Cell MyelomaActive, not recruitingNCT02538198Phase 2
• Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)CompletedNCT02537054Phase 2
• Study of DS-7080a for the Treatment of Macular DegenerationCompletedNCT02530918Phase 1
• Strategies for Management of Recurrent PterygiumStatus unknownNCT02530801Phase 4
• Retinal Sensitivity in BRVO After Anti-VEGF TherapyStatus unknownNCT02527733Phase 4
• HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02TerminatedNCT02525302Phase 2
• Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral SuspensionCompletedNCT02521714Phase 1
• Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical StudyStatus unknownNCT02520219Phase 2
• Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous CarcinomaStatus unknownNCT02513342Phase 4
• Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate TransplantationCompletedNCT02513186Phase 1
• A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)CompletedNCT02511405Phase 3
• Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 StudyWithdrawnNCT02511067Phase 2
• Thalidomide in Treating Crohn's DiseaseCompletedNCT02501291Phase 2
• Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal CancerCompletedNCT02497157Phase 2
• Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLCCompletedNCT02497118Phase 4
• Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal VasculopathyCompletedNCT02495181Phase 4
• Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast CancerStatus unknownNCT02489409Phase 2
• Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF InjectionStatus unknownNCT02486484Phase 2
• A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)Active, not recruitingNCT02483312Phase 1
• Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein OcclusionCompletedNCT02478515Phase 4
• Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCTCompletedNCT02472691Phase 2
• Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma PatientsCompletedNCT02471820Phase 2
• Phase I - Pharmacokinetic Comparability Study in Healthy Male VolunteersCompletedNCT02469987Phase 1
• Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical CancerCompletedNCT02467907Phase 2
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell LymphomaCompletedNCT02460276Phase 2
• Evaluation the Pharmacokinetics, Safety, Tolerability of BCD-021 in Patients With Neovascular Age-related Macular DegenerationWithdrawnNCT02450981Phase 1
• Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid TumorsCompletedNCT02450123Not applicable
• 25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical TrialStatus unknownNCT02447185Phase 3
• A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal CarcinomaCompletedNCT02444949Phase 2
• Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular EdemaCompletedNCT02441907Phase 4
• VITAL - Individualising Therapy for Neovascular AMD With AfliberceptCompletedNCT02441816Phase 4
• Avastin/FOLFIRI in Combination With Curcumin in Colorectal Cancer Patients With Unresectable MetastasisCompletedNCT02439385Phase 2
• Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or BevacizumabActive, not recruitingNCT02436993Phase 2
• Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected AdultsCompletedNCT02431767Phase 1
• Clinical Study of CWP232291 in Relapsed or Refractory Myeloma PatientsCompletedNCT02426723Phase 1
• Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT02420860Phase 2
• Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple MyelomaActive, not recruitingNCT02415413Phase 2
• Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System TumorsCompletedNCT02415153Phase 1
• Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT02410694Phase 2
• Intravitreal Aflibercept Injection for Symptomatic Macular Edema From Retinal Artery MacroaneurysmsStatus unknownNCT02403128Phase 1
• Irinotecan Plus Thalidomide in Second Line Advanced Gastric CancerStatus unknownNCT02401971Phase 4
• A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular DegenerationCompletedNCT02401945Phase 2
• A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced MelanomaWithdrawnNCT02400385Phase 2
• Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple MyelomaTerminatedNCT02400242Phase 1
• Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian CancerCompletedNCT02399592Phase 2
• A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.Status unknownNCT02398552Phase 2
• Variable Interval Versus Set Interval Aflibercept for DMECompletedNCT02392364Phase 4
• Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma PatientsWithdrawnNCT02389543Phase 1/2
• Gefitinib Combined With Thalidomide to Treat NSCLCStatus unknownNCT02387086Phase 2/3
• INC280 Combined With Bevacizumab in Patients With Glioblastoma MultiformeCompletedNCT02386826Phase 1
• Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) PatientsCompletedNCT02384083Phase 1/2
• Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept TreatmentCompletedNCT02381730Not applicable
• Multiple Treatments for Ebola Virus Disease (EVD)Status unknownNCT02380625Phase 1/2
• Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR MutationsStatus unknownNCT02375022Phase 2
• Lenalidomide and Obinutuzumab for Previously Untreated CLLWithdrawnNCT02371590Phase 2
• Evaluation of the Immune Restoration Potential Of LenalidomideWithdrawnNCT02371577Phase 2
• Study of Gemcitabine+Platinum Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24)CompletedNCT02363751Phase 2
• Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult PatientsStatus unknownNCT02354313Phase 3
• Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian CancerCompletedNCT02354131Phase 1/2
• FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-typeCompletedNCT02350530Phase 2
• Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal CancerCompletedNCT02350517Phase 2
• Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.Status unknownNCT02350361Phase 2/3
• Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME)WithdrawnNCT02349516Phase 2
• Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 YearCompletedNCT02348528Phase 2
• NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First RelapseWithdrawnNCT02348255Phase 2
• Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot StudyCompletedNCT02342392Phase 2/3
• Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRCStatus unknownNCT02339116Phase 3
• SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance TherapyActive, not recruitingNCT02334865Phase 1
• PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal CancerStatus unknownNCT02331927Phase 2
• Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer PatientsStatus unknownNCT02330783Phase 2
• Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular DegenerationStatus unknownNCT02328209Not applicable
• 25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in ChinaStatus unknownNCT02328118Phase 2/3
• An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes MellitusTerminatedNCT02324491Phase 2
• Cohort Study of the Clinical Course of Macular Diseases in KagawaStatus unknownNCT02321267Phase 4
• Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)CompletedNCT02320474Phase 4
• Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and BevacizumabCompletedNCT02316327Phase 4
• Bevacizumab Therapy for Brain Arteriovenous MalformationCompletedNCT02314377Phase 1
• Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell TransplantationCompletedNCT02312102Phase 1
• Prospective, Randomized Clinical Trial Comparing Macular Photocoagulation With or Without Intravitreal Bevacizumab or Triamcinolone for the Treatment of Diabetic Macular EdemaCompletedNCT02310295Not applicable
• Intravitreal Aflibercept in Neovascular AMD With Limited Response to RanibizumabCompletedNCT02309281Phase 4
• Intravitreous Bevacizumab and Standard Metabolic Control for Diabetic Macular Edema - A Contrast Sensitivity StudyCompletedNCT02308644Phase 3
• Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in ChildrenCompletedNCT02308527Phase 2
• Prophylactic Ranibizumab for Exudative Age-Related Macular DegenerationCompletedNCT02302989Phase 1/2
• Study of Lenalidomide in Relapse/Refractory Waldenstrom MacroglobulinemiaCompletedNCT02302469Phase 1/2
• A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)CompletedNCT02302079Phase 2
• Retreatment and Its Efficiency of Thalidomide for Vascular Malformation Patients With Failure of First Course TreatmentWithdrawnNCT02301949Phase 2
• Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced CancerActive, not recruitingNCT02298959Phase 1
• The Endurance 1 TrialCompletedNCT02297204Phase 4
• Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration PatientsStatus unknownNCT02296567Phase 2/3
• Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone AcetonideCompletedNCT02294656Phase 1
• Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I StudyCompletedNCT02287558Phase 1
• SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM PatientsCompletedNCT02283775Phase 1
• A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular EdemaWithdrawnNCT02281292Phase 1
• Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaWithdrawnNCT02281279Phase 1/2
• Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend RegimenCompletedNCT02274259Phase 4
• Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal CancerCompletedNCT02271464Phase 2

← Angiogenesis Inhibitors overview